U.S. Markets open in 8 hrs 51 mins
  • S&P Futures

    4,032.50
    0.00 (0.00%)
     
  • Dow Futures

    33,782.00
    -3.00 (-0.01%)
     
  • Nasdaq Futures

    11,949.25
    -18.75 (-0.16%)
     
  • Russell 2000 Futures

    1,894.60
    +1.10 (+0.06%)
     
  • Crude Oil

    77.60
    -0.30 (-0.39%)
     
  • Gold

    1,935.90
    -3.30 (-0.17%)
     
  • Silver

    23.72
    -0.02 (-0.08%)
     
  • EUR/USD

    1.0845
    -0.0012 (-0.1084%)
     
  • 10-Yr Bond

    3.5510
    -3.5180 (-100.00%)
     
  • Vix

    19.94
    -18.51 (-100.00%)
     
  • GBP/USD

    1.2342
    -0.0012 (-0.0975%)
     
  • USD/JPY

    130.2980
    -0.0600 (-0.0460%)
     
  • BTC-USD

    22,869.82
    -807.23 (-3.41%)
     
  • CMC Crypto 200

    518.95
    -18.92 (-3.52%)
     
  • FTSE 100

    7,784.87
    +19.72 (+0.25%)
     
  • Nikkei 225

    27,381.94
    -51.46 (-0.19%)
     

I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022

GAITHERSBURG, MD. and SHANGHAI, China, Oct. 5, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will present new preclinical data of its core assets lemzoparlimab and uliledlimab, respectively, at the 37th Society for Immunotherapy of Cancer's (SITC) Annual Meeting in Boston, MA, as well as virtually November 8-12, 2022.

(PRNewsfoto/I-Mab)
(PRNewsfoto/I-Mab)

Details of the poster presentations are as follows:

Title: 

Combination of Lemzoparlimab and HER2 ADC Elicits Enhanced Activity against HER2 Expressing Tumors

Abstract ID:

859

Presenter:

Dr. Fanny Zhang, I-Mab

Date/Time:

Thursday, November 10, 2022, 9:00 a.m. - 9:00 p.m. ET

 

Title: 

Revealing Novel Immune Modulatory Mechanism of Uliledlimab through the Blockade of CD73 Pathway

Abstract ID:

1151

Presenter:

Dr. Fanny Zhang, I-Mab

Date/Time:

Thursday, November 10, 2022, 9:00 a.m. - 9:00 p.m. ET

 

Full text of the abstracts will be released on the SITC website at 8:00 a.m. ET on Monday, November 7, 2022, and the posters will be available on the Company's website on November 12, 2022.

About CD47 and Lemzoparlimab

CD47 is a cell surface protein over-expressed in a wide variety of cancers and can act to protect tumors by delivering a "don't eat me" signal to otherwise tumor-engulfing macrophages.  CD47 antibody blocks this signal and enables macrophages to attack tumor cells. However, development of CD47 antibody as a cancer therapy has been hampered by its hematologic side effects, such as severe anemia, caused by natural binding of CD47 antibody to red blood cells. Scientists at I-Mab discovered a novel CD47 antibody, lemzoparlimab, that is designed to target tumor cells while exerting a minimal untoward effect on red blood cells.

Multiple clinical studies of lemzoparlimab are ongoing to explore indications in treating patients with myelodysplastic syndrome (MDS), acute myelocytic leukemia (AML), non-Hodgkin's lymphoma (NHL), and advanced solid tumors in combination with chemotherapy and immune checkpoint inhibitors.

About Uliledlimab

Uliledlimab (also known as TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Adenosine in turn binds to adenosine receptors on relevant immune cells and inhibits anti-tumor immune responses in tumor microenvironment. Uliledlimab is expected to offer clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Uliledlimab is effective in anti-tumor activities through a unique intra-dimer binding, leading to differentiated and favorable functional properties as evident in preclinical studies.

About I-Mab

I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development and soon, commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company's Fast-to-Proof-of-Concept and Fast-to-Market development strategies through internal R&D and global partnerships and commercial partnerships. I-Mab has established its global footprint in Shanghai, Beijing, Hangzhou, Guangzhou, Lishui and Hong Kong in China, and Maryland and San Diego in the United States.  For more information, please visit http://www.i-mabbiopharma.com and follow I-Mab on LinkedIn, Twitter, and WeChat.

I-Mab Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding data from preclinical studies of lemzoparlimab or uliledlimab, the potential implications of clinical data for patients, and I-Mab's advancement of, and anticipated clinical development, regulatory milestones, and commercialization of lemzoparlimab or uliledlimab. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to I-Mab's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or NDA/BLA approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of I-Mab's drug candidates; I-Mab's ability to achieve commercial success for its drug candidates, if approved; I-Mab's ability to obtain and maintain protection of intellectual property for its technology and drugs; I-Mab's reliance on third parties to conduct drug development, manufacturing and other services; I-Mab's limited operating history and I-Mab's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; and the impact of the COVID-19 pandemic on the Company's clinical development, commercial and other operations, as well as those risks more fully discussed in the "Risk Factors" section in I-Mab's most recent annual report on Form 20-F, as well as discussions of potential risks, uncertainties, and other important factors in I-Mab's subsequent filings with the US Securities and Exchange Commission. All forward-looking statements are based on information currently available to I-Mab, and I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

I-Mab Contacts

Richard Yeh

Chief Operating Officer, Interim Chief Financial Officer

IR@i-mabbiopharma.com

 

Gigi Feng

Chief Communications Officer  

 PR@i-mabbiopharma.com

 

Investor Inquiries

The Piacente Group, Inc.

Emilie Wu

E-mail: emilie@thepiacentegroup.com

Office line: +86 21 6039 8363

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-announces-poster-presentations-of-cd47-antibody-lemzoparlimab-and-cd73-antibody-uliledlimab-at-sitc-2022-301641244.html

SOURCE I-Mab